Terms: = Ovarian cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Clinical Outcome
12 results:
1. Phosphoproteomics identify arachidonic-acid-regulated signal transduction pathways modulating macrophage functions with implications for ovarian cancer.
Dietze R; Hammoud MK; Gómez-Serrano M; Unger A; Bieringer T; Finkernagel F; Sokol AM; Nist A; Stiewe T; Reinartz S; Ponath V; Preußer C; von Strandmann EP; Müller-Brüsselbach S; Graumann J; Müller R
Theranostics; 2021; 11(3):1377-1395. PubMed ID: 33391540
[TBL] [Abstract] [Full Text] [Related]
2. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and erk pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract] [Full Text] [Related]
3. Involvement of AF1q/MLLT11 in the progression of ovarian cancer.
Tiberio P; Lozneanu L; Angeloni V; Cavadini E; Pinciroli P; Callari M; Carcangiu ML; Lorusso D; Raspagliesi F; Pala V; Daidone MG; Appierto V
Oncotarget; 2017 Apr; 8(14):23246-23264. PubMed ID: 28423573
[TBL] [Abstract] [Full Text] [Related]
4. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract] [Full Text] [Related]
5. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract] [Full Text] [Related]
6. Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.
Itamochi H; Oumi N; Oishi T; Taniguchi F; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
Int J Gynecol Cancer; 2015 May; 25(4):570-6. PubMed ID: 25756405
[TBL] [Abstract] [Full Text] [Related]
7. Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome.
Leng R; Liao G; Wang H; Kuang J; Tang L
Med Oncol; 2015 Feb; 32(2):329. PubMed ID: 25585684
[TBL] [Abstract] [Full Text] [Related]
8. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/erk and JNK pathways.
Chang MC; Chen CA; Chen PJ; Chiang YC; Chen YL; Mao TL; Lin HW; Lin Chiang WH; Cheng WF
Biochem J; 2012 Mar; 442(2):293-302. PubMed ID: 21999204
[TBL] [Abstract] [Full Text] [Related]
9. High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer.
Wolf AM; Rumpold H; Reimer D; Marth C; Zeimet AG; Wolf D
Gynecol Oncol; 2010 Sep; 118(3):244-50. PubMed ID: 20603238
[TBL] [Abstract] [Full Text] [Related]
10. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.
Davidson B; Espina V; Steinberg SM; Flørenes VA; Liotta LA; Kristensen GB; Tropé CG; Berner A; Kohn EC
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):791-9. PubMed ID: 16467090
[TBL] [Abstract] [Full Text] [Related]
11. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions.
Givant-Horwitz V; Davidson B; Lazarovici P; Schaefer E; Nesland JM; Tropé CG; Reich R
Gynecol Oncol; 2003 Oct; 91(1):160-72. PubMed ID: 14529677
[TBL] [Abstract] [Full Text] [Related]
12. Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/erkM.
Calabrese C; Frank A; Maclean K; Gilbertson R
J Biol Chem; 2003 Jul; 278(27):24951-9. PubMed ID: 12709419
[TBL] [Abstract] [Full Text] [Related]
